LIU, W.,
ZHUANG, R.,
BAI, X.,
JIA, Z.,
KAPORA, E.,
TAN, W.,
FENG, S. (2020) (lncRNAs) have been proposed as therapeutic targets in CC. Hence, the present study
evaluatedРоль неоадъювантной гормонотерапии в лечении рака молочной железы: что мы знаем на данный момент?В. В. Воротников,
V. V. Vorotnikov,
Р. А. Пахомова,
R. A. Pakhomova,
А. В. Сойнов,
A. V. Soinov,
А. С. Гунина,
A. S. Gunina,
И. В. Копытич,
I. V. Kopytich,
М. Г. Цой,
M. G. Tsoi,
С. А. Абдугаффоров,
S. A. Abdugafforov (Креативная хирургия и онкология, №3, 2022) Preoperative Hormone Therapy in the
Treatment of Breast Cancer: What Do We Know So Far?
Beylerli, Ozal,
Shi, Huaizhang,
Begliarzade, Sema,
Shumadalova, Alina,
Ilyasova, Tatiana,
Sufianov, Albert (2024) avenues for exploration. These ncRNAs exert influence over the prognosis and
treatment resistance of brain
. It was revealed that strain OBA 2.4.1 is tolerant of up to 2 mM CdCl2, and seed
treatment with the bacterium